The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The main challenges that remain in diagnosing AL amyloidosis
Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, outlines key challenges that remain in the diagnosis of light chain (AL) amyloidosis. First, this disease is rare, and often has clinical presentations which mimic other more prevalent conditions. Furthermore, there is limited disease awareness in the medical community, and particularly amongst cardiologists, who, when suspecting amyloidosis, often first think of transthyretin (ATTR) amyloidosis. Finally, even when clinicians suspect AL amyloidosis correctly, the requirement for histological demonstration of amyloid deposits followed by the need for highly advanced diagnostic tools makes the diagnosis itself challenging. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
